NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued on Thursday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

NASDAQ NURO opened at $3.57 on Thursday. The firm has a market cap of $7.10 million, a P/E ratio of -0.57 and a beta of 2.26. The stock’s 50-day moving average is $3.74 and its 200-day moving average is $3.82. NeuroMetrix has a one year low of $2.70 and a one year high of $11.82.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings results on Thursday, February 22nd. The medical device company reported ($1.43) EPS for the quarter. The business had revenue of $1.32 million for the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%.

Institutional Investors Weigh In On NeuroMetrix

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in NeuroMetrix in the 4th quarter valued at approximately $43,000. Cerity Partners LLC acquired a new stake in NeuroMetrix in the 4th quarter valued at approximately $108,000. Millennium Management LLC raised its position in NeuroMetrix by 102.3% in the 4th quarter. Millennium Management LLC now owns 20,530 shares of the medical device company’s stock valued at $30,000 after buying an additional 10,384 shares during the last quarter. Renaissance Technologies LLC raised its position in NeuroMetrix by 30.7% in the 4th quarter. Renaissance Technologies LLC now owns 36,854 shares of the medical device company’s stock valued at $55,000 after buying an additional 8,654 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in NeuroMetrix by 11.1% in the 3rd quarter. Vanguard Group Inc. now owns 350,029 shares of the medical device company’s stock valued at $977,000 after buying an additional 34,892 shares during the last quarter. Institutional investors and hedge funds own 19.40% of the company’s stock.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.